The ideal treatment for any disease is one that can cure it or prevent spreading with minimal impact on the patient’s quality of life. In the case of cancer, therapeutic agents were initially designed to kill rapidly dividing cells. Dr Jean Pierre Wery, President of Crown Bioscience, reflects on the use of preclinical models to drive immunotherapy cancer research and combination strategies highlighting syngenic mouse models for immunotherapy and radiotherapy, combination therapies and strategies.